Included studies basic characteristics. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FVC. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

All data extracted. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for TNF- by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Effect of overexpressing <i>CEBPB</i> and <i>GFI-1</i> on <i>SOST</i> expression. by Avneesh Chopra (20927514)

Bias risk assessment of included studies. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for hs-CRP. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for IL-6. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The incidence rate of adverse reactions. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The PRISMA study flowchart. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FEV1/FVC. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for clinical efficacy. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FEV1. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The excluded and included studies were listed. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for PaCO₂. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for PaO₂. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The quality metrics of 4C-seq data. by Tingting Jiang (169999)

“…Functional assays demonstrated that targeted repression of Pparα-En4 region significantly decreased <i><i>Ppar</i>α</i> expression and impaired brown adipocyte differentiation and thermogenesis. …”

Uncropped western blot images. by Tingting Jiang (169999)

“…Functional assays demonstrated that targeted repression of Pparα-En4 region significantly decreased <i><i>Ppar</i>α</i> expression and impaired brown adipocyte differentiation and thermogenesis. …”

The values used to build graphs in the paper. by Tingting Jiang (169999)

“…Functional assays demonstrated that targeted repression of Pparα-En4 region significantly decreased <i><i>Ppar</i>α</i> expression and impaired brown adipocyte differentiation and thermogenesis. …”

The PCR primers of constructed vectors. by Tingting Jiang (169999)

“…Functional assays demonstrated that targeted repression of Pparα-En4 region significantly decreased <i><i>Ppar</i>α</i> expression and impaired brown adipocyte differentiation and thermogenesis. …”